IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors

Autor: Dorina Ujvari, Alena Malyukova, Ana Zovko, Elham Yektaei-Karin, Harsha S Madapura, Marton Keszei, Noemi Nagy, Kourosh Lotfi, Niclas Björn, Jonas Wallvik, Leif Stenke, Daniel Salamon

Publikováno v: OncoImmunology, Vol 11, Iss 1 (2022)

Tyrosine kinase inhibitors (TKIs) have dramatically improved the survival in chronic myeloid leukemia (CML), but residual disease typically persists even after prolonged treatment. Several lines of evidence suggest that TKIs administered to CML patie

Externí odkaz: https://doaj.org/article/692c9e23d3cf44459c340c094d0cbebe

Multiplexed single‐cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells

Autor: Emma Rörby, Jörgen Adolfsson, Erik Hultin, Thomas Gustafsson, Kourosh Lotfi, Jörg Cammenga, Jan-Ingvar Jönsson

Publikováno v: Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-14 (2021)

Abstract Background Fms-related tyrosine kinase 3 (FLT3) receptor serves as a prognostic marker and therapeutic target in acute myeloid leukemia (AML). Approximately one-third of AML patients carry mutation in FLT3, associated with unfavourable progn

Externí odkaz: https://doaj.org/article/1dba84575ec44799a51953ec59e38b1b

Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System

Autor: Karthik Selvaraju, Kourosh Lotfi, Johannes Gubat, Maria Miquel, Amanda Nilsson, Julia Hill, Lasse D. Jensen, Stig Linder, Pádraig D’Arcy

Publikováno v: Biomolecules, Vol 11, Iss 9, p 1339 (2021)

Dienone compounds with a 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore have been widely reported to show tumor cell selectivity. These compounds target the ubiquitin-proteasome system (UPS), known to be essential for the viability of tumor cells. Th

Externí odkaz: https://doaj.org/article/e3a3556452d440918e8c8e8c7d8df7fb

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Autor: Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B.L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek

Publikováno v: Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Nösslinger, T, Janssens, A, Christiansen, I, Baumann, M, Frederiksen, H, van der Klift, M, Jäger, U, Leys, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H, Enggaard, L, Goede, J, Regelink, J C, Widmer, A, Simon, F, De Silva, N, Fink, A-M, Bahlo, J, Fischer, K, Wendtner, C-M, Kreuzer, K A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, van Oers, M, Geisler, C, Stilgenbauer, S, Hallek, M, German CLL Study Group (GCLLSG), Haemato-Oncology Foundation for Adults in the Netherlands (HOVON), Nordic CLL Study Groups, Swiss Group for Clinical Cancer Research (SAKK), The Israeli CLL Association & Cancer Trials Ireland 2023, ' First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia ', The New England Journal of Medicine, vol. 388, no. 19, pp. 1739-1754 . https://doi.org/10.1056/NEJMoa2213093

BACKGROUNDRandomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.METHODSIn a phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57065540dd32adf0cc1d031449d13807
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e

Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Autor: Shady Adnan Awad, Olli Dufva, Jay Klievink, Ella Karjalainen, Aleksandr Ianevski, Paavo Pietarinen, Daehong Kim, Swapnil Potdar, Maija Wolf, Kourosh Lotfi, Tero Aittokallio, Krister Wennerberg, Kimmo Porkka, Satu Mustjoki

Publikováno v: Blood. 140:799-800

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d05c2d8b87ef306cb3874752e4e55bf
https://doi.org/10.1182/blood-2022-165247